Overview of the global hospital-acquired urinary tract infection testing market

Technavio’s market research analyst predicts the global hospital-acquired urinary tract infection testing market to grow at a CAGR of around 19% between 2016 and 2020. Urinary tract infection occupies the largest share in the HAIs category, and the number is constantly growing. This has encouraged several vendors to develop innovative testing products that will subsequently augment the demand for hospital-acquired urinary tract infection testing products. Several technological advancements have enhanced the testing procedures for urinary tract infection, as they are more precise, sensitive, generate faster outcomes, and provide a broader range of pathogen detection as compared with the most traditional methods. Moreover, the innovative techniques in bioinformatics and software programs help manage a massive amount of data and offer better-quality results from tests such as molecular diagnostics. These methods provide initiation of infection control practices, optimization of treatment selection, reduced hospital stay, and improved surveillance of infectious diseases. Also, hospitals are setting up infection control committees that focus on only HAIs. Such infection control committee is responsible for the evaluation and planning of evidence-based practice, resource allocation, and prioritization of matters related to infection control.

Geographically, the Americas dominated the market and accounted for the largest market share in 2015. The high prevalence of infectious diseases, leading to the increased demand for diagnostic products and services and focus on disease management has propelled market growth in this region. The US is the largest revenue contributor for the hospital-acquired UTI testing market in the Americas owing to the massive sales of infectious disease diagnostic products and urology devices. Moreover, factors like increased laboratory automation, the shift toward rapid POC diagnostic tests, and approval of new products by the Food and Drug Administration (FDA) will further boost the market’s growth in the coming years.

Competitive landscape and key vendors

The global hospital-acquired UTI testing device market is highly fragmented with the presence of large, medium, and small-sized companies. The key vendors in the market are forming partnerships and offering premium-priced products to sustain their market shares. However, the local vendors are selling products at lower prices, which is posing a serious threat to the large companies. The increasing prevalence of infectious diseases gives significant opportunities to the life science companies to focus on their R&D investments on devices for the efficient diagnosis of infectious diseases. Companies such as Siemens Healthineers, bioMerieux, Roche Diagnostics, and Beckman Coulter have expanded their product portfolio for diagnosis of most communicable diseases. Moreover, constant advances in technology, and innovative product launches will further increase the competition among vendors.

Leading vendors in the market are -

• bioMérieux
• Roche Diagnostics
• Siemens Healthineer

Other prominent vendors in the hospital-acquired UTI testing market include ACON Laboratories, Alere, ARKRAY, Beckman Coulter, Becton Dickinson and Company (BD), Bio-Rad, Cepheid, Labomed, Mindray, Sysmex, Thermo Fisher Scientific, and URIT Medical.

Segmentation by product and analysis of the hospital-acquired UTI testing market

• Assay kits and consumables
• Instruments

The assay kits and consumables segment accounts for the largest market share and generates a high return on investments for manufacturers, as they are used in greater quantities for sample analysis. Some assay kits are highly precise to certain pathogens. Consumables are used in bulk during sample analysis and multiple times. Multistix 10 SG reagent strips from Siemens Healthineers is one of the widely-used reagents strips to detect the UTIs in the market.

End-user segmentation and analysis of the hospital-acquired UTI testing market

• Hospitals and outpatient department
• Diagnostics clinical laboratories

Hospitals occupy a larger share of the hospital-acquired UTI testing market, as the surgery for urinary incontinence, urinary retention, and prostate or genitals procedures are more common in hospitals. Most of the UTIs happen especially in the ICUs due to the increased usage of urinary catheters. The increase in HAIs in individuals annually prompts the hospital authorities to make more investments in this sector. With the increasing number of hospitals worldwide, the revenue in the UTI test market will also increase substantially. Moreover, several hospitals are also opting for advanced technological UTI testing systems to maintain high revenues in the overall UTI testing market.

Key questions answered in the report include

• What will the market size and the growth rate be in 2020?
• What are the key factors driving the global hospital-acquired UTI testing market?
• What are the key market trends impacting the growth of the global hospital-acquired UTI testing market?
• What are the challenges to market growth?
• Who are the key vendors in the global hospital-acquired UTI testing market?
• What are the market opportunities and threats faced by the vendors in the global hospital-acquired UTI testing market?
• Trending factors influencing the market shares of the Americas, APAC, and EMEA.
• What are the key outcomes of the five forces analysis of the global hospital-acquired UTI testing market?

Technavio also offers customization on reports based on specific client requirement.

Related reports:

• Global Urinary Catheters Market 2016-2020
• Global Hospital Infection Therapeutics Market 2015-2019
• Global Urinary Incontinence Products Market 2015-2019